[Federal Register Volume 84, Number 91 (Friday, May 10, 2019)]
[Notices]
[Pages 20644-20645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-09618]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or

[[Page 20645]]

[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the Technology Transfer and Intellectual Property Office, National 
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, 
Rockville, MD 20852; tel. 301-496-2644. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Continuous Cell Lines Persistently Expressing High Levels of Native 
HIV-1 Envelope Trimers on Their Surface Membrane

    Description of Technology: Transduced human cell lines expressing 
high levels of native HIV-1 Envelope on their surface membrane, in the 
unmodified or interdomain stabilized form. These cell lines provide a 
stable source of native HIV-1 envelope for multiple uses, including the 
high-efficiency production of virus-like particles (VLPs) for use as 
vaccines, testing new inhibitors or neutralizing antibodies, or 
identifying/capturing B cells that produce broadly neutralizing 
antibodies from infected/vaccinated humans or animals.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     High-efficiency production of virus-like particles (VLPs).
     A means to test new inhibitors or neutralizing antibodies 
targeting HIV-1 envelope trimers.
     Probe for identifying/capturing B cells that produce 
broadly neutralizing antibodies.
    Competitive Advantages:
     The interdomain-stabilized form does not bind CD4 and is 
locked in the native prefusion form.
    Development Stage:
     Research Use.
    Inventors: Paolo Lusso (NIAID), Peng Zhang (NIAID).
    Publications: Zhang, Peng, et al. ``Interdomain stabilization 
impairs CD4 binding and improves immunogenicity of the HIV-1 envelope 
trimer.'' Cell host & microbe 23.6 (2018): 832-844.
    Licensing Contact: To license this technology please reference E-
185-2018-0, and contact Chris Kornak at 240-627-3705 or 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Chris Kornak at 240-627-3705 or 
[email protected].

    Dated: April 30, 2019.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2019-09618 Filed 5-9-19; 8:45 am]
BILLING CODE 4140-01-P